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Is the average elderly Norwegian at high risk of cardiovas-
cular disease after 60 years of age? Will most of these men
and women need health care or even drug treatment in
order to lower serum lipids and/or blood pressure? Well,
according to the present guidelines of the European Heart
Association, this actually seems to be the case.1 Hartz
et al.2 show that in Tromsø, Norway, the vast majority of
men .60 years, and females .70, have a 10-year risk of
fatal cardiovascular disease exceeding 5%, the suggested
limit for intervention. We can argue about the exact
ﬁgures, including the (unpublished) conﬁdence interval of
the 5% limit, but the main message is clear: it is normal to
be at ‘high’ risk. And what is true for Norway would be
true for most other European countries.
However, many clinicians will ﬁnd this deﬁnition of
normality hard to accept. Some will object simply on the
basis of semantics: the ‘average’ can never be equal to
‘high’. Some will feel that it is unethical to turn the majority
of seemingly healthy citizens into patients requiring medical
treatment and surveillance. When it comes to long-term
pharmacological treatment, many doctors are still wonder-
ing whether all-cause mortality is signiﬁcantly lowered by
drug treatment and whether study participants were repre-
sentative of their own patients in clinical practice. Some
will argue that the necessary societal expenses could be
better used for other purposes, unless each person covers
all the costs for screening and treatment. Some will say
that it is normal to die if you are old. However, most
elderly people will be glad to postpone death and disability,
if an efﬁcient option is available.
Certainly, in secondary prevention, the efﬁciency of drug
treatment is evident.3 Virtually, all of us agree to treat
average or high serum cholesterol and blood pressure in
patients with established cardiovascular disease, although
the evidence from randomized controlled trials is stronger
for statins than for antihypertensives. After myocardial
infarction, the prescription of low-dose aspirin and
beta-blockers is also based on solid evidence, as is the use
of ACE-inhibitors in high-risk patients. And in the Heart
Protection Study, simvastatin prevented one of four
strokes in subjects with a prior cerebrovascular event
irrespective of pre-existing coronary disease. Substantial
evidence also suggests that patients with diabetes should
have lower than ‘normal’ levels of blood pressure and LDL
cholesterol. Among the total Tromsø population studied by
Hartz et al.,2 aged 45–79, roughly one-third of the ‘high’
risk subjects belonged to this secondary prevention group,
i.e. people with self-reported cardiovascular disease
(myocardial infarction, angina pectoris, stroke, or intermit-
tent claudication) or diabetes.
In primary prevention, however, things are a bit more
complicated.3 It is still uncertain if total mortality is
decreased by drug treatment in subjects in the lower
range of ‘high’ initial risk of cardiovascular death. Even
more uncertain is whether aggressive treatment is more
effective than a less aggressive one, with regard to the
dose and number of drugs. These uncertainties apply to
both mild hypertension and dyslipidaemia. Before telling
the average citizen that long-term medication is beneﬁcial,
it would therefore be preferable to have a more solid scien-
tiﬁc base than what we have today. In primary prevention, it
is particularly important to scrutinize the validity of the
European SCORE risk charts in this aspect. Computer-based
score systems and standardization of risk factor measure-
ments may further improve risk evaluations at the individual
level, for example, if waist circumference and HDL choles-
terol are included in the model.
Age as a risk factor poses a particular problem. Much
evidence suggests that in the elderly, antihypertensives
are more effective and statins equally effective as in
younger people. As the absolute cardiovascular risk is
higher, the absolute beneﬁt may therefore increase with
age, possibly well above 70 years. However, a beneﬁcial
effect on total mortality in the elderly has been shown for
antihypertensives but not for lipid lowering. Drug treatment
patterns among the Tromsø population study suggest that
there is (compared with European guidelines) a very large
underprescription of antihypertensives and, in particular,
lipid-lowering drugs after the age of 65. Hartz et al.2
suggest that the validity of the guidelines for elderly
individuals be carefully re-evaluated.
However, let us, for a moment, leave all these uncertain-
ties and accept the fact that the average middle-aged
or elderly European, even in Mediterranean countries,
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sooner or later will be at high risk of stroke or cardiovascular
death. The most important underlying condition, athero-
sclerosis, affects to a high degree the coronary arteries of
virtually everyone who has passed the age of 60, even in
southern Europe.4 Although advanced atherosclerosis is a
typical consequence of ageing today, early human autopsy
studies and animal experiments suggest that it is not
an inevitable process.5 An international autopsy study in
the 1960s comparing middle-aged men in four countries
revealed a marked difference, depending on the degree of
urbanization.6 Other free-living mammals are apparently
not affected by advanced coronary atherosclerosis unless
they are fed a diet not available in their natural habitat,
and atherosclerosis promotion and regression in animal
experiments are highly responsive to dietary manipulation,
in particular, one that is in concert with the animal’s
natural diet.5
Others and we have found reasonably good evidence that
human populations with lifestyles resembling that of our
pre-agricultural ancestors have no or little cardiovascular
disease, despite sufﬁcient numbers of elderly.5,7 Clinical
studies strongly suggest that both stroke and coronary
heart disease were absent before urbanization in such popu-
lations.7,8 Cardiovascular risk factor levels have been
remarkably beneﬁcial and very different from those among
Western populations, most consistently with regard to
blood pressure and the metabolic syndrome.5 The lowest
levels of blood pressure (typically 110/70+ 15/10 mmHg)
and serum cholesterol (typically 3+ 1 mmol/L) have been
noted in hunter-gatherers with very high intakes of meat.
Furthermore, in several recent dietary intervention trials,
Jenkins et al.9 have obtained effective lowering of LDL
cholesterol with cereal- and dairy-free, plant-based diets,
in fact, as effective as with statin treatment. Possibly, the
common denominator is avoidance of foods that are new
to the human species.
Our concept of normality obviously depends on whether
we believe that these recent but common risk proﬁles are
unavoidable or not. If all citizens were smokers, we would
certainly not object to classify the average risk of fatal
lung cancer as high, even if the 10-year risk in that case
would be less than 5%. We would then use non-smokers as
the norm despite their absence in our own population.
Hence, it seems obvious that there is a large potential to
prevent cardiovascular disease in Europe. Smoking absten-
tion, regular physical activity, and healthy diets are import-
ant steps towards this goal, as ﬁrmly stated in the European
guidelines.1 At the societal level, healthy lifestyles need to
be strongly promoted and subsidized. With regard to diet,
increasing evidence suggests that the prevailing concepts
may need considerable modiﬁcation before food becomes
an efﬁcient tool in the prevention and treatment of cardio-
vascular disease. Although randomized dietary trials are
difﬁcult to perform, the enormous amount of money spent
so far in randomized drug trials (the recently published
ASCOT study was estimated to about 300 billion Euros)
must sooner or later be equalled in the search for optimal
dietary modiﬁcation. We believe that our evolu-
tionary legacy may provide a reference standard in that
search.5,8,10,11
In summary, the study by Hartz et al. adds to the evidence
that the majority of Europeans should take their future risk
of cardiovascular disease seriously. The European guidelines
are a valuable starting point for clinicians to be much more
active in this process, as long as the position of the guideline
writers has not been undermined by better arguments. I
think it would be a mistake to adjust the guidelines only
because they show that few of us are healthy.
Conﬂict of interest: none declared.
References
1. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R,
Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G,
Manger Cats V, Orth-Gromer K, Perk J, Pyorala K, Rodicio JL, Sans S,
Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D. European guidelines
on cardiovascular disease prevention in clinical practice. Third Joint Task
Force of European and Other Societies on Cardiovascular Disease
Prevention in Clinical Practice. Eur Heart J 2003;24:1601–1610.
2. Hartz I, Njølstad I, Eggen AE. Does implementation of the European
guidelines based on the SCORE model double the number of Norwegian
adults who need cardiovascular drugs for primary prevention? The
Tromsø study 2001. Eur Heart J 2005;26:2673–2680. First published on
October 4, 2005, doi:10.1093/eurheartj/ehi556.
3. Clinical Evidence Writers. Clinical Evidence. The International Source of
the Best Available Evidence for Effective Health Care. London: BMJ
Publishing Group; 2005.
4. Bertomeu A, Garcia-Vidal O, Farre X, Galobart A, Vazquez M, Laguna JC,
Ros E. Preclinical coronary atherosclerosis in a population with low
incidence of myocardial infarction: cross sectional autopsy study. BMJ
2003;327:591–592.
5. Lindeberg S, Cordain L, Eaton SB. Biological and clinical potential of a
palaeolithic diet. J Nutr Environ Med 2003;13:1–12.
6. Tejada C, Strong JP, Montenegro MR, Restrepo C, Solberg LA. Distribution
of coronary and aortic atherosclerosis by geographic location, race, and
sex. Lab Invest 1968;18:509–526.
7. Lindeberg S, Lundh B. Apparent absence of stroke and ischaemic heart
disease in a traditional Melanesian island: a clinical study in Kitava.
J Intern Med 1993;233:269–275.
8. Lindeberg S. Stroke in Papua New Guinea. Lancet Neurol 2003;2:273.
9. Jenkins DJ, Popovich DG, Kendall CW, Vidgen E, Tariq N, Ransom TP,
Wolever TM, Vuksan V, Mehling CC, Boctor DL, Bolognesi C, Huang J,
Patten R. Effect of a diet high in vegetables, fruit, and nuts on serum
lipids. Metabolism 1997;46:530–537.
10. Cordain L, Eaton SB, Sebastian A, Mann N, Lindeberg S, Watkins BA,
O’Keefe JH, Brand-Miller J. Origins and evolution of the Western diet:
health implications for the 21st century. Am J Clin Nutr
2005;81:341–354.
11. Eaton SB, Strassman BI, Nesse RM, Neel JV, Ewald PW, Williams GC,
Weder AB, Eaton SE 3rd, Lindeberg S, Konner MJ, Mysterud I, Cordain L.
Evolutionary health promotion. Prev Med 2002;34:109–118.
2606 Editorial
 by guest on A
pril 23, 2016
http://eurheartj.oxfordjournals.org/
D
ow
nloaded from
 
